MX2017016835A - Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. - Google Patents

Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.

Info

Publication number
MX2017016835A
MX2017016835A MX2017016835A MX2017016835A MX2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A
Authority
MX
Mexico
Prior art keywords
methods
individual
treating autoimmune
alloimmune
present disclosure
Prior art date
Application number
MX2017016835A
Other languages
English (en)
Inventor
Panicker Sandip
Parry Graham
A Nikitin Pavel
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of MX2017016835A publication Critical patent/MX2017016835A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona métodos para tratar un trastorno aloinmunitario o autoinmunitario en un individuo; en donde los métodos implican administrar al individuo una cantidad eficaz de un anticuerpo específico para un componente del complemento Cls. La presente descripción proporciona un método para monitorear la eficacia de un método de tratamiento de un sujeto; en donde el método implica detectar el nivel de autoanticuerpo o aloanticuerpo en una muestra biológica obtenida del individuo.
MX2017016835A 2015-06-26 2016-06-23 Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. MX2017016835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
PCT/US2016/039087 WO2016210172A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Publications (1)

Publication Number Publication Date
MX2017016835A true MX2017016835A (es) 2018-08-01

Family

ID=57585852

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016835A MX2017016835A (es) 2015-06-26 2016-06-23 Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.
MX2023002021A MX2023002021A (es) 2015-06-26 2017-12-19 Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002021A MX2023002021A (es) 2015-06-26 2017-12-19 Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.

Country Status (13)

Country Link
US (2) US20180169240A1 (es)
EP (1) EP3313417A4 (es)
JP (1) JP6963509B2 (es)
KR (1) KR20180020296A (es)
CN (1) CN108348600A (es)
AU (2) AU2016282782A1 (es)
BR (1) BR112017027578A2 (es)
CA (1) CA2990662A1 (es)
EA (1) EA038567B1 (es)
HK (1) HK1254030A1 (es)
IL (1) IL256424B1 (es)
MX (2) MX2017016835A (es)
WO (1) WO2016210172A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
EP3280440B1 (en) 2015-04-06 2022-11-16 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
PT3448419T (pt) * 2016-04-29 2023-07-26 Brigham & Womens Hospital Inc Anticorpos contra o interferão beta e sua utilização
AU2020368745A1 (en) * 2019-10-16 2022-04-21 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
EP4337332A2 (en) 2021-07-13 2024-03-20 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
CA2720682A1 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
CN102597005A (zh) * 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
JP6538561B2 (ja) * 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
CA2889197A1 (en) * 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof

Also Published As

Publication number Publication date
EP3313417A4 (en) 2019-06-12
IL256424A (en) 2018-02-28
AU2016282782A1 (en) 2018-01-18
CA2990662A1 (en) 2016-12-29
HK1254030A1 (zh) 2019-07-12
EP3313417A1 (en) 2018-05-02
KR20180020296A (ko) 2018-02-27
CN108348600A (zh) 2018-07-31
BR112017027578A2 (pt) 2018-08-28
WO2016210172A1 (en) 2016-12-29
IL256424B1 (en) 2024-05-01
JP6963509B2 (ja) 2021-11-10
JP2018526330A (ja) 2018-09-13
MX2023002021A (es) 2023-03-15
EA038567B1 (ru) 2021-09-15
EA201890106A1 (ru) 2018-05-31
US20180169240A1 (en) 2018-06-21
US20220249664A1 (en) 2022-08-11
AU2022215307A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
MX2023002021A (es) Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
MX364886B (es) Lente oftálmica con sistema microfluídico.
PH12017502222A1 (en) Lag-3-binding molecules and methods of use thereof
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
MX2017001138A (es) Metodo.
WO2014169226A3 (en) Methods of diagnosing and treating chronic pain
ZA201800498B (en) Anti¿pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
MX2013012284A (es) Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
MX2015017807A (es) Sistema cerrado integrado de extraccion de linea intravenosa.
EA201691647A1 (ru) Способы кратковременного и долгосрочного лечения зависимости от лекарственных средств
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX2018012939A (es) Moleculas de union especificas para receptor fc gamma humano iia y usos de las mismas.
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
FR3029016B1 (fr) Procede d'enrichissement d'une electrode d'un dispositif electrochimique en espece ionique.
MX2017016337A (es) Tratamiento de carcinoma de linea media nut.
MX2016012278A (es) Deteccion temprana de preeclampsia.
WO2014138176A3 (en) Apparatus and method for analyzing blood clotting
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
EA201691168A1 (ru) Способы исследования бета-глюкана
FR3003576B1 (fr) Dispositif et procede de traitement de cellules graisseuses, notamment pour nettoyer et filtrer les cellules graisseuses d’un patient en vue d’un lipofilling